Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer reports positive results from phase III trial of Pregabalin
The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in
The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in
The study, which recreated five earlier drug cardiac safety studies, utilized the proprietary Early Precision QT methodology developed by iCardiac Technologies. The results show highly significant improvement in
R.C. Taylor is a leading regional distributor of products and supplies for convenience stores, grocery chains, independent grocers and specialty stores in Texas and New Mexico. The purchase
"This patent covers the significant innovations we have made in the delivery of therapeutic proteins into mitochondria," said Dalia Megiddo, MD, Chief Executive Officer of BioBlast. "We are
The new app, at www.iodine.com/cold-and-flu, helps people sift through the 300+ options in the cold and flu aisle to find and compare medications that treat their own combination
PharmaDirections’ expertise will assist CannaPharmaRx with drug discovery, API process development, preclinical pharmacology and toxicology studies, formulation development, drug substance/drug product GMP manufacturing and regulatory submissions. "CannaPharmaRx is
Pursuant to the agreement Adapt has received from Lightlake a global license to develop and commercialize Lightlake’s intranasal naloxone opioid overdose reversal treatment. In exchange for licensing its
Its lead compound PPL-003 showed success in two studies in rabbits. In the first study, topical eye administration of PPL-003 at the highest feasible dose was well tolerated
PPD and ERT will work closely throughout all areas of the clinical development process to offer clients efficiencies through alignment of crucial aspects of service delivery, including budget
The Company believes this is an important breakthrough discovery for two reasons. The first is that it confirms that TRXE-009 is an important new potential treatment for melanoma,